Theravance Biopharma Stock Price and Value Analysis

Should you buy Theravance Biopharma stock? (NasdaqGM:TBPH). Let's see how it does in our automated value investing analysis system.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Theravance Biopharma to reach your target.

Target type

TBPH Free Cash Flow Trend

Free Cash Flow trendline for TBPH
Free Cash Flow trendline for Theravance Biopharma

Hmm, we can't give any reliable projection for Theravance Biopharma's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company has amazingly consistent growth!
  • This stock looks overpriced.
  • This company is not making money.
  • This company is less known than others.
  • This company pays no dividend.

Inside the TBPH Numbers

TBPH Price
(Theravance Biopharma stock price per share)
$17.02
[?] PE Ratio versus Sector 19% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 10%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,618,508 shares shorted. With 25,857,097 shares available for purchase and an average trading volume over the past 10 trading days of 315,490, it would take at least 5.13 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Is Theravance Biopharma Stock on Sale?

Based on our analysis, we believe that you should not buy Theravance Biopharma right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Advertisement supports free stock analysis content.

Should You Buy TBPH Stock?

Does Theravance Biopharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: TBPH

This example shows how we apply the Trendshare checklist to TBPH: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 17.02
    • Market cap: $884M
    • EPS: 1.04
  2. Step 2 — Valuation checks

    • P/E: 16.365
    • FCF yield: —
    • Date checked: Sep 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.

Most Popular Articles